Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants

Carl T D'Angio1, Paulina A Boohene, Anne Mowrer

  • 1Department of Pediatrics, University of Rochester, Rochester, NY 14642, USA. carl_dangio@urmc.rochester.edu

Pediatrics
|March 3, 2007
PubMed

Insights

Extremely preterm infants showed similar antibody responses to measles, mumps, rubella, and varicella vaccines compared to term infants at 15 months. This indicates comparable immunogenicity for these crucial childhood vaccinations.

Area of Science:

  • Pediatrics
  • Immunology
  • Vaccinology

Background:

  • Extremely preterm infants often exhibit diminished antibody responses to vaccines compared to full-term infants.
  • Understanding vaccine immunogenicity in preterm infants is crucial for establishing effective immunization schedules.

Purpose of the Study:

  • To compare the immunogenicity of measles-mumps-rubella (MMR) and varicella vaccines in preterm and term infants.
  • To assess antibody titers before and after vaccination at 15 months of age.

Main Methods:

  • A comparative study involving 32 infants (16 preterm, 16 term) vaccinated at 15 months.
  • Antibody titers for measles, mumps, rubella, and varicella were measured using plaque reduction neutralization assay and ELISA.
  • Geometric mean antibody titer (GMT) was the primary outcome measure.

Main Results:

  • Preterm infants had lower pre-vaccination GMTs for mumps and rubella.
  • Post-vaccination GMTs for measles, mumps, rubella, and varicella were similar between preterm and term groups.
  • High seropositivity rates were observed in both groups after vaccination for all antigens.

Conclusions:

  • Preterm children achieve comparable antibody responses to MMR and varicella vaccines as term children by 15 months of age.
  • These findings support the use of standard vaccination schedules for preterm infants.
Abstract

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Vaccinations01:51

Vaccinations

Overview
Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...